Tachyphylaxis after intravitreal bevacizumab for exudative age-related macular degeneration.

@article{Forooghian2009TachyphylaxisAI,
  title={Tachyphylaxis after intravitreal bevacizumab for exudative age-related macular degeneration.},
  author={Farzin Forooghian and Catherine A. Cukras and Catherine B. Meyerle and Emily Y. Chew and Wai T Wong},
  journal={Retina},
  year={2009},
  volume={29 6},
  pages={723-31}
}
PURPOSE To describe tachyphylaxis to intravitreal bevacizumab (IVB) in patients with exudative age-related macular degeneration (AMD). METHODS We retrospectively reviewed the records of 59 consecutive patients treated with IVB at the National Eye Institute over a 14-month period and identified cases demonstrating loss of treatment efficacy as revealed by spectral domain optical coherence tomography. We defined tachyphylaxis as a loss of therapeutic response to IVB 28 +/- 7 days after… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 61 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 19 references

Ranibizumab for neovascular age-related macular degeneration.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists • 2008

Similar Papers

Loading similar papers…